

GIVING LIFE TO SCIENCE™



Notice of Results

March 10, 2020

RNS Number : 5158F
PureTech Health PLC
10 March 2020

10 March 2020

PureTech Health plc

Notice of Results

PureTech Health plc (LSE: PRTC) ("PureTech," or the "Company") plans to announce its financial results for the year ended 31 December 2019 on Thursday, 9 April 2020.

A presentation and conference call for analysts will take place at 2:00pm BST / 9:00am EDT, and a webcast of the presentation will be available on the Company's website at <http://puretechhealth.com/investors> under the Reports and Presentations tab. PureTech also confirms that the global outbreak of COVID-19 has not adversely affected the Company's business of addressing major diseases through its leadership in immunology and the Brain-Immune-Gut (BIG) Axis. The Company has a very strong cash position and is advancing the business in accordance with its previously announced strategy and timelines while continuing to monitor the situation.

About PureTech Health

PureTech is a clinical stage biotherapeutics company dedicated to discovering, developing and commercialising highly differentiated medicines for devastating diseases, including intractable cancers, lymphatic and gastrointestinal diseases, central nervous system disorders and inflammatory and immunological diseases, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech's affiliates, is comprised of 23 product candidates and one product that has been cleared by the US Food and Drug Administration (FDA). All of the underlying programmes and platforms that resulted in this pipeline of product candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on the Company's unique insights into the biology of the brain, immune and gut, or BIG, systems and the interface between those systems, referred to as the BIG Axis.

For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

Forward Looking Statement

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

Investors EU media

Allison Mead Talbot	Ben Atwell, Rob Winder
+1 617 651 3156	+44 (0) 20 3727 1000
amt@puretechhealth.com ben.atwell@FTIconsulting.com	

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.lseg.com.